Literature DB >> 3966415

Milk and plasma lipid composition in a lactating patient with type I hyperlipoproteinemia.

G Steiner, J J Myher, A Kuksis.   

Abstract

This report describes studies on the plasma and milk lipid composition of a patient with primary Type I hyperlipoproteinemia who had been followed through her second pregnancy. Post-partum she lactated, supplying milk for assay. It was abnormal in the low content of its total lipid and in the bizarre composition of its fatty acids. The proportion of long chain fatty acids was unusually low, and that of medium chain fatty acids unusually high. Furthermore, the fatty acids of the patient's milk differed greatly from those of her plasma triglycerides. This was in marked contrast to normal nursing mothers' milk, in which the fatty acid composition is comparable to that of plasma triglycerides. The patient's milk fatty acids were shorter in chain length and deficient in essential fatty acids. During the time of lactation, the patient remained hyperlipidemic and her post-heparin plasma had no lipolytic activity. These data and the differences between the plasma and milk fatty acids suggested that in the patient the circulating triglyceride fatty acids did not enter the mammary gland. Without preformed fatty acids entering it from plasma or adipose tissue, the lactating breast apparently synthesized fatty acids de novo. These newly synthesized fatty acids were of medium, rather than long chain length. This accounted for the abundance of medium chain length triglycerides in the patient's milk. The studies suggested that the deficit of lipoprotein lipase in Type I hyperlipoproteinemia extended to the mammary gland.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3966415     DOI: 10.1093/ajcn/41.1.121

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  8 in total

1.  Lipoprotein lipase deficiency due to long-term heparinization presenting as severe hypertriglyceridaemia in pregnancy.

Authors:  G F Watts; J Cameron; A Henderson; W Richmond
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

2.  Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia.

Authors:  Gunilla Olivecrona; Ewa Ehrenborg; Henrik Semb; Elena Makoveichuk; Anna Lindberg; Michael R Hayden; Peter Gin; Brandon S J Davies; Michael M Weinstein; Loren G Fong; Anne P Beigneux; Stephen G Young; Thomas Olivecrona; Olle Hernell
Journal:  J Lipid Res       Date:  2009-12-21       Impact factor: 5.922

Review 3.  GPIHBP1, an endothelial cell transporter for lipoprotein lipase.

Authors:  Stephen G Young; Brandon S J Davies; Constance V Voss; Peter Gin; Michael M Weinstein; Peter Tontonoz; Karen Reue; André Bensadoun; Loren G Fong; Anne P Beigneux
Journal:  J Lipid Res       Date:  2011-08-15       Impact factor: 5.922

4.  Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene.

Authors:  Y Ma; M S Liu; D Ginzinger; J Frohlich; J D Brunzell; M R Hayden
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  A cross-species comparison of neutral lipid composition of milk fat of prosimian primates.

Authors:  J J Myher; A Kuksis; C Tilden; O T Oftedal
Journal:  Lipids       Date:  1994-06       Impact factor: 1.880

Review 6.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 7.  Human milk in disease: lipid composition.

Authors:  M Hamosh; J Bitman
Journal:  Lipids       Date:  1992-11       Impact factor: 1.880

8.  Multiple pathways ensure retinoid delivery to milk: studies in genetically modified mice.

Authors:  Sheila M O'Byrne; Yuko Kako; Richard J Deckelbaum; Inge H Hansen; Krzysztof Palczewski; Ira J Goldberg; William S Blaner
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-29       Impact factor: 4.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.